Cerus Corporation
CERS
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Sysā¦ read more
Healthcare
Medical Devices
28 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$2.06
Price-1.44%
-$0.03
1Y
Price
Market Cap
$395.439m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+4.9%
EBITDA Margin+0.0%
Net Profit Margin+0.2%
Free Cash Flow Margin+4.9%
EBITDA Margin+0.0%
Net Profit Margin+0.2%
Free Cash Flow MarginRevenue
$199.191m
+10.5%
1y CAGR+7.4%
3y CAGR+11.5%
5y CAGREarnings
-$15.964m
+23.7%
1y CAGR+26.8%
3y CAGR+25.4%
5y CAGREPS
-$0.08
+27.3%
1y CAGR+29.1%
3y CAGR+28.1%
5y CAGRBook Value
$62.204m
$215.185m
Assets$152.981m
Liabilities$98.186m
DebtDebt to Assets
45.6%
-16.7x
Debt to EBITDAFree Cash Flow
$168k
-98.0%
1y CAGR-17.7%
3y CAGR-8.1%
5y CAGRNo items found.
Press Releases
Statements and updates from the company